Clin Lab. 2023 Jul 1;69(7). doi: 10.7754/Clin.Lab.2022.221231.
Refractoriness to platelet transfusion has not been adequately studied in pediatric patients with thrombocytopenia. Our objectives were: (1) to describe the practice of platelet transfusion in pediatric patients with thrombocytopenia of various etiologies; (2) to assess the responsiveness to platelet transfusions and clinical variables affecting platelet transfusions response; and (3) to evaluate incidence of PTR.
A retrospective study included pediatric patients with thrombocytopenia admitted to a tertiary children's hospital who received ≥ 1 platelet transfusion during hospitalization. Responsiveness was measured by corrected count increment (CCI), poor platelet transfusion response (PPTR), and platelet transfusion refractoriness (PTR).
A total of 334 patients were eligible for the study and received 1,164 transfusions, with a median of 2 (IQR: 1 - 5) platelet transfusions. Patients admitted with hematologic malignancies had the highest median number of platelet transfusions (5, IQR: 4 - 10). The median CCI of 1,164 platelet post-transfusions was 17.0 (IQR: 9.4 - 24.6) and the incidence of PPTR was 11.9%. Patients admitted with ITP had the lowest median CCI (7.6, IQR: 1.0 - 12.5) and the highest incidence of PPTR (36.4%, 8/22). Older age of platelet components, low doses of platelet transfusion, increasing number of platelet transfusions (≥ 5), splenomegaly, bleeding, DIC, shock, ECMO supported, and HLA antibody-positive were independent risk factors for PPTR. Finally, the incidence of PTR was 11.4%.
Practical experience of clinicians regarding the use of apheresis platelets in pediatric patients is determined. Highlight that PTR is not a low probability event when apheresis platelets are received in pediatric patients.
血小板减少症患儿的血小板输注抵抗尚未得到充分研究。我们的目标是:(1)描述各种病因所致血小板减少症患儿血小板输注的实践情况;(2)评估血小板输注的反应性及影响血小板输注反应的临床变量;(3)评估血小板输注无效(PTR)的发生率。
本回顾性研究纳入了因血小板减少症而入住三级儿童医院的儿科患者,这些患者在住院期间至少接受过 1 次血小板输注。通过校正血小板计数增加值(CCI)、血小板输注不良反应(PPTR)和血小板输注抵抗(PTR)来衡量反应性。
共有 334 例患者符合入选标准,并接受了 1164 次输注,中位数为 2(IQR:1-5)次血小板输注。因血液病而入院的患者接受的血小板输注中位数最高(5,IQR:4-10)。1164 次血小板输注后的中位数 CCI 为 17.0(IQR:9.4-24.6),PPTR 的发生率为 11.9%。因 ITP 而入院的患者 CCI 中位数最低(7.6,IQR:1.0-12.5),PPTR 的发生率最高(36.4%,8/22)。血小板成分的年龄较大、血小板输注剂量较低、血小板输注次数(≥5 次)增加、脾肿大、出血、DIC、休克、ECMO 支持和 HLA 抗体阳性是 PPTR 的独立危险因素。最后,PTR 的发生率为 11.4%。
确定了临床医生在儿科患者中使用单采血小板的实际经验。强调当儿科患者接受单采血小板时,PTR 并不是低概率事件。